Patrick Lyden, MD

Professor of Physiology and Neuroscience, Neurology and Neurological Surgery

NINDS/Neuro Next Program Support

Image of Patrick Lyden, MD
Is this your profile? Click to edit

Overview

Dr. Lyden is the Professor of Physiology & Neuroscience and Neurology at the Zilkha Neurogenetic Institute in the Keck School of Medicine at USC. Dr. Lyden helped lead the pivotal NINDS t-PA for Acute Stroke Trial, the first proven therapy for stroke. He is recognized globally for leadership in stroke therapy, having led large, multi-national trials for NIH and industry. Dr. Lyden is the Principal investigator of the NINDS-sponsored Stroke Preclinical Assessment Network, or SPAN, the first multi-site trial intended to identify candidate treatments likely to succeed in human clinical trials. He is the Chair of the Stroke Council of the American Heart Association/American Stroke Association. Dr. Lyden has been elected a Fellow of the American Academy of Neurology, American Neurology Association, American Heart Association, and the European Stroke Organization. In 2019 he was awarded the prestigious William M. Feinberg Award for Excellence in Clinical Stroke by the American Heart Association. Beginning in 2023 he will lead a 100-center, $20M clinical trial of a new drug for stroke treatment in the NIH funded StrokeNet network.

Awards

  • Cedars-Sinai Medical Center: Faculty Teaching Award, 2020
  • UT Houston: Gladys & George T. Abell Lecturship in Neurology, 2019
  • American Heart Association/American Stroke Association: AHA/ASA William M. Feinberg Award for Excellence in Clinical Stroke, 2019
  • University of Iowa: Adolf L. Sahs, MD Memorial Visiting Lecturer, 2011
  • 2001
     -: Best Doctors in America, 2001
     –
  • UCSD: Department of Neurosciences Award for Outstanding Teaching, 2014
  • American Heart Association, San Diego Affiliate: Heart of Gold Award, 2002

Education and Training

  • UCLA, Los Angeles — BS — 07/1974 — Biochemistry
  • Baylor College of Medicine, Houston — MD — 061981 — Medicine
  • Mercy Hospital, San Diego — 06/1982 — Internship
  • UCSD, San Diego — 06/1985 — Neurology
  • UCSD, San Diego — 06/1987 — Vascular Neurology

Research Funding

  • Mechanisms and Treatment Implications of Differential Vulnerability in the Central Nervous System
    NIH · RF1NS146594 · Aug 18, 2026 – Jul 31, 2029 · Role: Principal Investigator
  • The NIH SPAN Coordinating Center
    NIH · U24NS130600 · Jan 1, 2023 – Dec 31, 2025 · Role: Principal Investigator
  • The NIH SPAN Coordinating Center
    NIH · U24NS113452 · Aug 1, 2019 – Jul 31, 2022 · Role: Principal Investigator
  • ZZ-3K3A-201: Safety evaluation of 3K3A-APC in ischemic stroke
    NIH · U01NS088312 · Jul 1, 2014 – Jun 30, 2019 · Role: Principal Investigator
  • Thrombin mediated cytotoxicity during cerebral ischemia
    NIH · R01NS075930 · Aug 15, 2011 – May 31, 2021 · Role: Principal Investigator
  • Quantitation of Early Vascular Leakage after Stroke
    NIH · R21NS052565 · Jul 15, 2005 – Apr 30, 2008 · Role: Principal Investigator
  • Role of Angiogenesis Following Stroke
    NIH · R01NS043300 · Dec 15, 2002 – Jun 30, 2008 · Role: Principal Investigator
  • Therapeutic Window for Acute Stroke Therapy (P50)
    NIH · P50NS044148 · Jul 1, 2002 – Apr 30, 2015 · Role: Co-Principal Investigator
  • MULTIFOCAL CEREBRAL ISCHEMIA
    NIH · R29NS026783 · Aug 1, 1989 – Jul 31, 1994 · Role: Principal Investigator

Publications

  • Acute neuropathological consequences of short-term mechanical ventilation in wild-type and Alzheimer’s disease mice. Crit Care. 2019 02 22; 23(1):63.. View in PubMed
  • Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann Neurol. 2019 01; 85(1):125-136.. View in PubMed
  • Studies Targeting Stroke and Acute Myocardial Infarction. Ther Hypothermia Temp Manag. 2019 03; 9(1):8-12.. View in PubMed
  • Differential effects of hypothermia on neurovascular unit determine protective or toxic results: Toward optimized therapeutic hypothermia. J Cereb Blood Flow Metab. 2019 09; 39(9):1693-1709.. View in PubMed
  • Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease. J Stroke Cerebrovasc Dis. 2019 Feb; 28(2):360-368.. View in PubMed
  • Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol. 2018 10; 17(10):885-894.. View in PubMed
  • Unique Uses of Cooling Strategies. Ther Hypothermia Temp Manag. 2018 09; 8(3):126-130.. View in PubMed
  • Can an anticoagulant reduce brain hemorrhage: Invited comment on “Dabigatran reduces endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization”. Thromb Res. 2018 Jun 12.. View in PubMed
  • Lack of Early Improvement Predicts Poor Outcome Following Acute Intracerebral Hemorrhage. Crit Care Med. 2018 04; 46(4):e310-e317.. View in PubMed
  • Retinal Microvascular Abnormalities as Surrogate Markers of Cerebrovascular Ischemic Disease: A Meta-Analysis. J Stroke Cerebrovasc Dis. 2018 Jul; 27(7):1960-1968.. View in PubMed